Chimeric antigen T-cell therapy combined with imatinib and chemotherapy in treatment of Philadelphia chromosome-like acute lymphoblastic leukemia with EBF1-PDGFRB-positive: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2018.09.007
- VernacularTitle:嵌合抗原受体T细胞联合伊马替尼及化疗治疗EBF1-PDGFRB阳性费城染色体样急性淋巴细胞白血病一例并文献复习
- Author:
Haiping DAI
1
;
Ting XU
;
Zheng LI
;
Jia YIN
;
Depei WU
;
Xiaowen TANG
Author Information
1. 215006,苏州大学附属第一医院血液科 江苏省血液研究所 卫生部血栓与止血重点实验室血液学协同创新中心
- Keywords:
Leukemia,lymphocytic,acute;
Gene fusion;
Receptor,platelet-derived growth factor β;
Protein-tyrosine kinases;
Drug therapy,combination;
CAR-T
- From:
Journal of Leukemia & Lymphoma
2018;27(9):536-538
- CountryChina
- Language:Chinese
-
Abstract:
Objective To improve the understanding of the diagnosis and treatment of Philadelphia (Ph) chromosome-like acute lymphoblastic leukemia (ALL) with EBF1-PDGFRB-positive. Methods One case of Ph-like ALL with EBF1-PDGFRB-positive from the First Affiliated Hospital of Soochow University was reported. Whole exome sequencing was applied to detect the EBF1-PDGFRB fusion gene. Fluorescence in situ hybridization (FISH) was used to detect minimal residual disease. Comprehensive treatments including chemotherapy, imatinib and chimeric antigen T-cell (CAR-T) therapy were utilized. Results EBF1-PDGFRB fusion gene in the bone marrow samples was detected by using whole exome sequencing at early diagnosis. The rearrangement of PDGFRB showed continuous negative after comprehensive therapy. The patient achieved continuous molecular remission for 22 months. Conclusions The comprehensive treatments include combined chemotherapy, CAR-T therapy and tyrosine kinase inhibitor can promote the continuous of major molecular remission for EBF1-PDGFRB-positive Ph-like ALL patients.
